
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.